Home » Stocks » KZR

Kezar Life Sciences, Inc. (KZR)

Stock Price: $5.32 USD -0.10 (-1.85%)
Updated Jan 20, 2021 1:25 PM EST - Market open
Market Cap 251.49M
Revenue (ttm) n/a
Net Income (ttm) -40.38M
Shares Out 50.00M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $5.32
Previous Close $5.42
Change ($) -0.10
Change (%) -1.85%
Day's Open 5.47
Day's Range 5.22 - 5.49
Day's Volume 120,995
52-Week Range 2.77 - 7.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-media...

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-medi...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and...

Seeking Alpha - 2 months ago

Kezar is a young company with two candidates in clinical development. Development programs with broad therapeutic potential.

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-medi...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-medi...

Business Wire - 2 months ago

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncol...

Business Wire - 3 months ago

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncol...

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

Seeking Alpha - 4 months ago

Kezar Life Sciences: Exploring New Options For Autoimmune Diseases

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

Seeking Alpha - 5 months ago

Kezar Life Sciences, Inc. (KZR) CEO John Fowler on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncol...

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

The Motley Fool - 7 months ago

The company's public offering of common stock doesn't exactly thrill investors.

The Motley Fool - 7 months ago

Kezar Life Sciences just released interim results on its only drug and shares jumped 70%. Now that the stock has settled, is it a good time to buy?

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...

Seeking Alpha - 7 months ago

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ABBV, ALDX
GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...

Zacks Investment Research - 8 months ago

Kezar Life Sciences (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 11th

Other stocks mentioned: BGS, NERV, W
Seeking Alpha - 8 months ago

Kezar Life Sciences: Key Catalysts Ahead

GlobeNewsWire - 8 months ago

SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics t...

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecul...

Zacks Investment Research - 9 months ago

Is (KZR) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...

GuruFocus - 11 months ago

Wall Street sell-side analysts recommend buying shares of Aurora Mobile Limited (NASDAQ:JG) and Kezar Life Sciences Inc (NASDAQ:KZR), two falling knives whose share prices lost more than 59% o...

Other stocks mentioned: JG
GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecu...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecul...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...

Benzinga - 1 year ago

Shares of Kezar Life Sciences Inc (NASDAQ: KZR) have retreated to a fresh 52-week low on roughly five times their average volume.

24/7 Wall Street - 1 year ago

Kezar Life Sciences Inc. shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus (SLE).

About KZR

Kezar Life Sciences, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
CEO
John Fowler
Employees
40
Stock Exchange
NASDAQ
Ticker Symbol
KZR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for KZR stock is "Strong Buy." The 12-month stock price forecast is 14.67, which is an increase of 175.75% from the latest price.

Price Target
$14.67
(175.75% upside)
Analyst Consensus: Strong Buy